{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T10:15:45Z","timestamp":1793614545885,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006203","name":"NASA | Johnson Space Center","doi-asserted-by":"publisher","award":["IPA"],"award-info":[{"award-number":["IPA"]}],"id":[{"id":"10.13039\/100006203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006203","name":"NASA | Johnson Space Center","doi-asserted-by":"publisher","award":["IPA"],"award-info":[{"award-number":["IPA"]}],"id":[{"id":"10.13039\/100006203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006203","name":"NASA | Johnson Space Center","doi-asserted-by":"publisher","award":["IPA"],"award-info":[{"award-number":["IPA"]}],"id":[{"id":"10.13039\/100006203","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Microgravity"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pharmaceuticals selected for exploration space missions must remain stable and effective throughout mission timeframes. Although there have been six spaceflight drug stability studies, there has not been a comprehensive analytical analysis of these data. We sought to use these studies to quantify the rate of spaceflight drug degradation and the time-dependent probability of drug failure resulting from the loss of active pharmaceutical ingredient (API). Additionally, existing spaceflight drug stability studies were reviewed to identify research gaps to be addressed prior to exploration missions. Data were extracted from the six spaceflight studies to quantify API loss for 36 drug products with long-duration exposure to spaceflight. Medications stored for up to 2.4 years in low Earth orbit (LEO) exhibit a small increase in the rate of API loss with a corresponding increase in risk of product failure. Overall, the potency for all spaceflight-exposed medications remains within 10% of terrestrial lot-matched control with a ~1.5 increase in degradation rate. All existing studies of spaceflight drug stability have focused primarily on repackaged solid oral medications, which is important because non-protective repackaging is a well-established factor contributing to loss of drug potency. The factor most detrimental to drug stability appears to be nonprotective drug repackaging, based on premature failure of drug products in the terrestrial control group. The result of this study supports a critical need to evaluate the effects of current repackaging processes on drug shelf life, and to develop and\n                    <jats:italic>validate<\/jats:italic>\n                    suitable protective repackaging strategies that help assure the stability of medications throughout the full duration of exploration space missions.\n                  <\/jats:p>","DOI":"10.1038\/s41526-023-00271-6","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:02:17Z","timestamp":1683270137000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The effect of long-term spaceflight on drug potency and the risk of medication failure"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-1623","authenticated-orcid":false,"given":"J. F.","family":"Reichard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-3208","authenticated-orcid":false,"given":"K. R.","family":"Lehnhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8095","authenticated-orcid":false,"given":"B. D.","family":"Easter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"271_CR1","unstructured":"Drake, B. G., Baker, J. D., Hoffman, S. J., Landau, D. & Voels, S. A. In Human Exploration of Mars Design Reference Architecture 5.0, Addendum #2 (ed Drake, B. G. & Watts, K. D.) 17\u201366 (NASA Johnson Space Center, Houston, 2014). https:\/\/www.nasa.gov\/sites\/default\/files\/files\/NASA-SP-2009-566-ADD2.pdf."},{"key":"271_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41526-020-00124-6","volume":"6","author":"ZS Patel","year":"2020","unstructured":"Patel, Z. S. et al. Red risks for a journey to the red planet: the highest priority human health risks for a mission to Mars. NPJ Microgravity 6, 33 (2020).","journal-title":"NPJ Microgravity"},{"key":"271_CR3","doi-asserted-by":"crossref","unstructured":"Hanson, A. et al. A Model-Based Systems Engineering Approach to Exploration Medical System Development, IEEE, 2019).","DOI":"10.1109\/AERO.2019.8741864"},{"key":"271_CR4","first-page":"129","volume":"2012","author":"S Bajaj","year":"2021","unstructured":"Bajaj, S., Sakhuja, N. & Singla, D. Stability testing of pharmaceutical products. J. Appl. Pharm. Sci. 2012, 129\u2013138 (2021).","journal-title":"J. Appl. Pharm. Sci."},{"key":"271_CR5","unstructured":"Bokser, A. D. & O\u2019Donnell, P. B. in Remington: Essentials of Pharmaceutics (ed Felton, L.) 37\u201349 (Pharmaceutical Press, London, 2013)."},{"key":"271_CR6","unstructured":"Wigent Rodney, J. in Remington: Essentials of Pharmaceutics Remington (ed Felton, L.) 301\u2013315 (Pharmaceutical Press, London, 2013)."},{"key":"271_CR7","unstructured":"Thomas, J. C. in Applied Physical Pharmacy 2e (eds Amiji, M. M., Cook, T. J. & Mobley W Cary) (McGraw-Hill, 2013)."},{"key":"271_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/jps.20636","volume":"95","author":"RC Lyon","year":"2006","unstructured":"Lyon, R. C., Taylor, J. S., Porter, D. A., Prasanna, H. R. & Hussain, A. S. Stability profiles of drug products extended beyond labeled expiration dates. J. Pharm. Sci. 95, 1549\u20131560 (2006).","journal-title":"J. Pharm. Sci."},{"key":"271_CR9","unstructured":"Wu, L. & Chow, D. Final report of NASA first award project. NASA 1\u201322 (2016)."},{"key":"271_CR10","unstructured":"Cory, W. C., James, V., Lamas, A., Mangiaracina, K. & Moon, J. Analysis of degradation of pharmaceuticals stored on the international space station. National Aeronautics and Space Administration (NASA) 1\u201325 (2016)."},{"key":"271_CR11","unstructured":"Cory, W. C., James, V. & Mangiaracina, K. Analysis of degradation of pharmaceuticals stored on the international space station - final report. National Aeronautics and Space Administration (NASA) 1\u201319 (2017)."},{"key":"271_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1208\/s12248-015-9834-5","volume":"18","author":"VE Wotring","year":"2016","unstructured":"Wotring, V. E. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J. 18, 210\u2013216 (2016).","journal-title":"AAPS J."},{"key":"271_CR13","unstructured":"Khan, M. & Wotring, V. E. FDA Comprehensive Stability Evaluation of Three Medications. NASA 1\u201382 (2014)."},{"key":"271_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1208\/s12248-011-9270-0","volume":"13","author":"B Du","year":"2011","unstructured":"Du, B. et al. Evaluation of physical and chemical changes in pharmaceuticals flown on space missions. AAPS J. 13, 299\u2013308 (2011).","journal-title":"AAPS J."},{"key":"271_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1208\/s12249-011-9588-z","volume":"12","author":"E Nelson","year":"2011","unstructured":"Nelson, E. & Huang, H. Practical considerations in the measurement of the internal relative humidity of pharmaceutical packages with data loggers. AAPS Pharm. Sci. Tech. 12, 331\u2013336 (2011).","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"271_CR16","doi-asserted-by":"publisher","unstructured":"USP. \u2329671\u232a Containers\u2014Performance Testing. General Chapter. United States Pharmacopeia 43, 6922 (2019). https:\/\/doi.org\/10.31003\/USPNF_M99430_03_01.","DOI":"10.31003\/USPNF_M99430_03_01"},{"key":"271_CR17","doi-asserted-by":"publisher","unstructured":"USP. \u2329661\u232a Plastic Packaging Systems and Their Materials of Construction, General Chapter. United States Pharmacopeia 43, 6887 (2019). https:\/\/doi.org\/10.31003\/USPNF_M99420_04_01.","DOI":"10.31003\/USPNF_M99420_04_01"},{"key":"271_CR18","unstructured":"US FDA. Q1E Evaluation of Stability Data. 1\u201316 (Food and Drug Administration, Rockville, 2004). https:\/\/www.fda.gov\/media\/71722\/download."},{"key":"271_CR19","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1208\/s12249-012-9815-2","volume":"13","author":"R Capen","year":"2012","unstructured":"Capen, R. et al. On the shelf life of pharmaceutical products. AAPS PharmSciTech 13, 911\u2013918 (2012).","journal-title":"AAPS PharmSciTech"},{"key":"271_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/009286151104500310","volume":"45","author":"ER van den Heuvel","year":"2011","unstructured":"van den Heuvel, E. R., Almalik, O., Nijhuis, M. B. & Warner, E. I. Statistical analysis for long-term stability studies with multiple storage conditions. Drug Inf. J. 45, 301\u2013314 (2011).","journal-title":"Drug Inf. J."},{"key":"271_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/10543409508835102","volume":"5","author":"JJ Chen","year":"1995","unstructured":"Chen, J. J., Hwang, J. & Tsong, Y. Estimation of the shelf-life of drugs with mixed effects models. J. Biopharm. Stat. 5, 131\u2013140 (1995).","journal-title":"J. Biopharm. Stat."},{"key":"271_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.2307\/2529472","volume":"33","author":"TB Kirkwood","year":"1977","unstructured":"Kirkwood, T. B. Predicting the stability of biological standards and products. Biometrics 33, 736\u2013742 (1977).","journal-title":"Biometrics"},{"key":"271_CR23","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/10543406.2014.888439","volume":"24","author":"O Almalik","year":"2014","unstructured":"Almalik, O., Nijhuis, M. B., van den Heuvel, & Edwin, R. Combined statistical analyses for long-term stability data with multiple storage conditions: a simulation study. J. Biopharm. Stat. 24, 493\u2013506 (2014).","journal-title":"J. Biopharm. Stat."},{"key":"271_CR24","unstructured":"US FDA. Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities; Guidance for Industry. 1\u201311 (Food and Drug Administration, Silver Spring, 2017). https:\/\/www.fda.gov\/media\/90978\/download."},{"key":"271_CR25","unstructured":"US FDA. Container Closure Systems for Packaging Human Drugs and Biologics; Guidance for Industry. 1\u201315 (US Food and Drug Administration, Rockville, 1999). https:\/\/www.fda.gov\/media\/70788\/download."},{"key":"271_CR26","unstructured":"US FDA. Expiration Dating of Unit-dose Repackaged Solid Oral Dosage form Drug Products; Guidance for Industry. 1\u20134 (US Food and Drug Administration, Silver Spring, 2020). https:\/\/www.fda.gov\/media\/70985\/download."},{"key":"271_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jpba.2016.12.040","volume":"136","author":"P Mehta","year":"2017","unstructured":"Mehta, P. & Bhayani, D. Impact of space environment on stability of medicines: challenges and prospects. J. Pharm. Biomed. Anal. 136, 111\u2013119 (2017).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"271_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41526-019-0076-1","volume":"5","author":"RS Blue","year":"2019","unstructured":"Blue, R. S. et al. Limitations in predicting radiation-induced pharmaceutical instability during long-duration spaceflight. NPJ microgravity 5, 15 (2019).","journal-title":"NPJ microgravity"},{"key":"271_CR29","doi-asserted-by":"crossref","unstructured":"Wotring, V. E. in Space Pharmacology (Springer US, New York, NY, 2012).","DOI":"10.1007\/978-1-4614-3396-5"},{"key":"271_CR30","doi-asserted-by":"publisher","unstructured":"USP. \u23291226\u232a Verification of Compendial Procedures, General Chapter. United States Pharmacopeia 43, 8171 (2019). https:\/\/doi.org\/10.31003\/USPNF_M870_03_01.","DOI":"10.31003\/USPNF_M870_03_01"},{"key":"271_CR31","unstructured":"US FDA. Analytical Procedures and Methods Validation for Drugs and Biologics; Guidance for Industry. 1\u201315 (US Food and Drug Administration, Silver Spring, 2015). https:\/\/www.fda.gov\/media\/87801\/download."},{"key":"271_CR32","doi-asserted-by":"publisher","unstructured":"USP. \u23297\u232a Labeling, General Chapter. United States Pharmacopeia 43, 6435 (2019). https:\/\/doi.org\/10.31003\/USPNF_M4908_11_01.","DOI":"10.31003\/USPNF_M4908_11_01"},{"key":"271_CR33","doi-asserted-by":"publisher","unstructured":"USP. \u23291178\u232a Good Repackaging Practices, General Chapter. United States Pharmacopeia 43, 8006 (2019). https:\/\/doi.org\/10.31003\/USPNF_M523_05_01.","DOI":"10.31003\/USPNF_M523_05_01"},{"key":"271_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bej.2004.10.007","volume":"23","author":"PA Bersanetti","year":"2005","unstructured":"Bersanetti, P. A., Almeida, R. M. R. G., Barboza, M., Ara\u00fajo, M. L. G. C. & Hokka, C. O. Kinetic studies on clavulanic acid degradation. Biochemical Eng. J. 23, 31\u201336 (2005).","journal-title":"Biochemical Eng. J."},{"key":"271_CR35","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1248\/cpb.29.3334","volume":"29","author":"J Haginaka","year":"1981","unstructured":"Haginaka, J., Nakagawa, T. & Uno, T. Stability of clavulanic acid in aqueous solutions. Chem. Pharm. Bull. 29, 3334\u20133341 (1981).","journal-title":"Chem. Pharm. Bull."},{"key":"271_CR36","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biotechadv.2008.03.002","volume":"26","author":"PS Saudagar","year":"2008","unstructured":"Saudagar, P. S., Survase, S. A. & Singhal, R. S. Clavulanic acid: a review. Biotechnol. Adv. 26, 335\u2013351 (2008).","journal-title":"Biotechnol. Adv."},{"key":"271_CR37","first-page":"11","volume":"48","author":"S Damle","year":"2016","unstructured":"Damle, S., Baweja, J., Sandoval, P., Teckoe, J. & Rajabi-Siahboomi, A. Coating moisture sensitive drugs for in-the-package and in-use protection. Pharma 48, 11\u201315 (2016).","journal-title":"Pharma"},{"key":"271_CR38","unstructured":"Strasser, C. Application note 117. Influence of humidity on the decomposition of potassium clavulanate. NETZSCH-Ger\u00e4tebau GmbH (2018). https:\/\/refworks.proquest.com\/library\/read\/doc:60c79d0a8f080d36ca321d93\/."},{"key":"271_CR39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/10837450.2013.852571","volume":"20","author":"J Cielecka-Piontek","year":"2015","unstructured":"Cielecka-Piontek, J., Paczkowska, M., Zalewski, P., Lewandowska, K. & Barszcz, B. Solid-state stability and compatibility studies of clavulanate potassium. Pharm. Dev. Technol. 20, 146\u2013152 (2015).","journal-title":"Pharm. Dev. Technol."},{"key":"271_CR40","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3109\/03639049809082720","volume":"24","author":"J Wardrop","year":"1998","unstructured":"Wardrop, J., Jaber, A. B. & Ayres, J. W. Multiple-layer compression-coated tablets: formulation and humidity studies of novel chewable amoxicillin\/clavulanate tablet formulations. Drug Dev. Ind. Pharm. 24, 729\u2013736 (1998).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"271_CR41","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/JOM.0000000000000158","volume":"56","author":"J Law","year":"2014","unstructured":"Law, J. et al. Relationship between carbon dioxide levels and reported headaches on the international space station. J. Occup. Environ. Med. 56, 477\u2013483 (2014).","journal-title":"J. Occup. Environ. Med."},{"key":"271_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fnsys.2019.00080","volume":"13","author":"KE Hupfeld","year":"2020","unstructured":"Hupfeld, K. E. et al. Neural correlates of vestibular processing during a spaceflight analog with elevated carbon dioxide (CO2): a pilot study. Front. Syst. Neurosci. 13, 80 (2020).","journal-title":"Front. Syst. Neurosci."},{"key":"271_CR43","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3109\/03639048809151998","volume":"14","author":"JT Carstensen","year":"1988","unstructured":"Carstensen, J. T. Effect Of Moisture On The Stability Of Solid Dosage Forms. Drug Dev. Ind. Pharm. 14, 1927\u20131969 (1988).","journal-title":"Drug Dev. Ind. Pharm."},{"key":"271_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1081\/PDT-120003494","volume":"7","author":"KC Waterman","year":"2002","unstructured":"Waterman, K. C. et al. Hydrolysis in pharmaceutical formulations. Pharm. Dev. Technol. 7, 113\u2013146 (2002).","journal-title":"Pharm. Dev. Technol."},{"key":"271_CR45","first-page":"75","volume":"5","author":"KC Waterman","year":"2004","unstructured":"Waterman, K. C., Adami, R. C. & Hong, J. Y. Impurities in drug products. Sep. Sci. Technol. 5, 75\u201388 (2004).","journal-title":"Sep. Sci. Technol."},{"key":"271_CR46","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1021\/ja01250a059","volume":"65","author":"HS Harned","year":"1943","unstructured":"Harned, H. S. & Davis, R. The ionization constant of carbonic acid in water and the solubility of carbon dioxide in water and aqueous salt solutions from 0 to 50\u00b0B. J. Am. Chem. Soc. 65, 2030\u20132037 (1943).","journal-title":"J. Am. Chem. Soc."},{"key":"271_CR47","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1002\/jps.23228","volume":"101","author":"RT Berendt","year":"2012","unstructured":"Berendt, R. T. et al. Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality. J. Pharm. Sci. 101, 2681\u20132685 (2012).","journal-title":"J. Pharm. Sci."},{"key":"271_CR48","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3109\/10837450903426518","volume":"15","author":"WC Cory","year":"2010","unstructured":"Cory, W. C., Harris, C. & Martinez, S. Accelerated degradation of ibuprofen in tablets. Pharm. Dev. Technol. 15, 636\u2013643 (2010).","journal-title":"Pharm. Dev. Technol."},{"key":"271_CR49","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1007\/s11095-012-0782-9","volume":"29","author":"AS Narang","year":"2012","unstructured":"Narang, A. S., Desai, D. & Badawy, S. Impact of excipient interactions on solid dosage form stability. Pharm. Res. 29, 2660\u20132683 (2012).","journal-title":"Pharm. Res."},{"key":"271_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijpharm.2004.12.013","volume":"293","author":"KC Waterman","year":"2005","unstructured":"Waterman, K. C. & Adami, R. C. Accelerated aging: prediction of chemical stability of pharmaceuticals. Int. J. pharmaceutics 293, 101\u2013125 (2005).","journal-title":"Int. J. pharmaceutics"},{"key":"271_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.publhealth.18.1.83","volume":"18","author":"KM Leung","year":"1997","unstructured":"Leung, K. M., Elashoff, R. M. & Afifi, A. A. Censoring issues in survival analysis. Annu. Rev. Public Health 18, 83\u2013104 (1997).","journal-title":"Annu. Rev. Public Health"}],"container-title":["npj Microgravity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41526-023-00271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41526-023-00271-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41526-023-00271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T07:09:39Z","timestamp":1683270579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41526-023-00271-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["271"],"URL":"https:\/\/doi.org\/10.1038\/s41526-023-00271-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1720710\/v1","asserted-by":"object"}]},"ISSN":["2373-8065"],"issn-type":[{"value":"2373-8065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no unreported financial or non-financial interests, affiliations, or involvement with any organization or entity discussed in this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}